Harboring BRAF V600 mutations in roughly 20–50% [112], Subbiah et al. showed a promising ORR of 69% (11 of 16) with dabrafenib and trametinib [113], ultimately leading to FDA approval of this BRAF/MEK combination for unresectable anaplastic thyroid carcinoma in 2018. Here, BRAF is linked to thyroid gland undifferentiated (anaplastic) carcinoma.